axitinib + gemcitabine + cisplatin

Axitinib + gemcitabine + cisplatin is a combination regimen of three pharmaceutical agents used in oncology, particularly for the treatment of advanced or metastatic cancers such as biliary tract cancer and non-small cell lung cancer. Axitinib is a potent and selective small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, thereby inhibiting angiogenesis required for tumor growth[1]. Gemcitabine is a nucleoside analog that interferes with DNA synthesis by incorporating into DNA during replication, leading to masked chain termination and apoptosis[2]. Cisplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication and transcription which results in cell death[5][6]. This combination leverages complementary mechanisms—antiangiogenic effects from axitinib with cytotoxic effects from gemcitabine and cisplatin—to enhance antitumor efficacy.

Other names

axitinib + gemcitabine + cisplatin